All Industries

Nursing Flowsheet Unveils Comprehensive Guides for Nurses to Achieve Financial Freedom

Rev Up Marketers

Nursing Flowsheet, a blog platform dedicated to empowering nurses, has provided educational resources, advice, and tools to help them achieve financial literacy and career growth. Nursing Flowsheet has provided detailed insights into nursing careers and helping nurses thrive and live their dream lives under the leadership of Ellaine Maala. With the recent update, Nursing Flowsheet has featured comprehensive guides on how to achieve financial freedom and helps potential users and nurses have a flourishing career. The platform provides users with the basic knowledge and understanding to gain financial independence. Nursing Flowsheet has become a platform to motivate and direct nurses to save money and build wealth by gaining informative and detailed financial education. With a zeal to help women live the life of their dreams, Nursing Flowsheet strives to provide valuable insights on helping nurses invest their hard-earned money and get financial freedom. Ellaine Maala, the founder of the blog platform Nursing Flowsheet, stated "When I was a newly graduated nurse, there weren’t any electronic medical records, instead, “Nursing Flowsheets” were used. This is where vital signs, intake and output, and assessment/treatment plans for patients are documented. In a way, this blog served as a place where I documented my experiences in nursing," says Elaine. "Eventually, I decided to write about my life experiences and my journey to financial freedom." For more details about Nursing Flowsheet and their services to empower nurses, please visit their website. About the Founder - Ellaine Maala: Before becoming a certified Nurse Practitioner, Ellaine worked as an ICU nurse and later learned personal finance through books, and courses and decided in 2021 to become a Certified Financial Education Instructor (CFEI) through the National Financial Educators Council. Having a strong grasp over personal finances, especially investing, Ellaine profoundly started to document her nursing experiences in the Nursing Flowsheet blog, sharing her journey to financial freedom. About Nursing Flowsheet: Founded by Ellaine Maala, a seasoned nurse herself, Nursing Flowsheet emerged from a deeply personal journey. It offers a wealth of educational materials, advice, and practical tools aimed at helping nurses navigate the complexities of personal finance and professional growth. Contact Details Nursing Flowsheet Ellaine Maala ellaine@nursingflowsheet.com Company Website https://nursingflowsheet.com/

March 19, 2024 05:29 PM Eastern Daylight Time

Image

Derwent Investments Provides Insight into Singapore's Budget 2023 and its Impact on the Investment Landscape

Rev Up Marketers

Following the recent announcement of Singapore’s Budget 2023, Derwent Investments, a leading wealth management company based in Singapore, has offered insights into the fiscal policies and their potential impact on the investment landscape. Chief Economist at Derwent Investments, Jingwei Chan, emphasized the importance of fiscal prudence in navigating the economic landscape. Chan commented, “The Budget 2023 reflects a delicate balance between addressing immediate needs and ensuring long-term resilience. With a projected deficit for FY2023, Singapore must carefully manage its resources to maintain competitiveness and sustain growth.” Highlighting the significance of the government’s approach in diversifying revenue sources, Chan noted, “The introduction of measures such as higher taxes on high-end properties and luxury cars demonstrates a commitment to equitable taxation. This balanced approach fosters economic stability while addressing social needs.” Edward Chandler, Director of Private Equity at Derwent Investments, discussed the implications of the budget for investors and businesses. Chandler stated, “Budget 2023 presents opportunities and challenges for investors. The focus on enhancing competitiveness and infrastructure investment aligns with the long-term investment strategy of Derwent Investments.” Chandler emphasised the importance of resilience amid global uncertainties, remarking, “As Singapore navigates through economic shifts, prudent investment strategies are crucial. Finance experts within the company remain optimistic about the investment landscape, leveraging their expertise to identify opportunities for clients.” Looking ahead, Derwent Investments anticipates the fiscal policies outlined in Budget 2023 to shape the investment landscape. According to Chan, “The prudent fiscal stance adopted by Singapore is essential for sustained growth and resilience. Derwent Investments is committed to providing clients with strategic investment solutions in line with the evolving economic landscape.” Derwent Investments remains dedicated to empowering clients with insights and expertise to navigate the dynamic investment landscape in Singapore and beyond. About Derwent Investments PTE. LTD: Derwent Investments is a leading Singapore-based Wealth Management company, providing comprehensive financial services and investment strategies to clients in the Asia-Pacific region. With a focus on delivering tailored solutions, Derwent Investments aims to empower clients to navigate the dynamic and ever-changing market. For more information about Derwent Investments, please visit https://www.derwentinv.com. For media inquiries, please contact: Mr. David Heng media@derwentinv.com Contact Details Derwent Investments PTE. LTD Mr. David Heng media@derwentinv.com Company Website https://www.derwentinv.com

March 19, 2024 04:49 PM Eastern Daylight Time

Image

Foster West Securities Explores Australian Fixed-Income Market Amid Market Volatility

Rev Up Marketers

Foster West Securities, a leading wealth management company based in Perth, is closely monitoring the Australian fixed-income market in light of recent market volatility. As the S&P/ASX 200 index experiences fluctuations attributed to various factors, including commodity prices and anticipation of the Reserve Bank's interest rate decision, the firm emphasises the importance of understanding fixed -income opportunities for investors seeking stability amidst uncertain times. Fixed-income investments, including government bonds, corporate bonds, and fixed-income exchange-traded funds (ETFs), have historically provided investors with regular income streams and potential defensive qualities against market uncertainties. However, in the current market environment, Foster West Securities refrains from promoting specific investment recommendations but instead encourages investors to conduct thorough research and seek professional advice tailored to their individual financial objectives and risk tolerance. Commenting on the market conditions, Luka Fischer, Senior Advisor at Foster West Securities, noted, "The recent volatility underscores the importance of a diversified investment approach. While fixed-income investments can offer stability and income, it's crucial for investors to carefully evaluate their suitability within the context of their overall portfolio." Simon Clarke, another Senior Advisor at Foster West Securities, echoed similar sentiments, stating, "In times of uncertainty, investors should prioritise capital preservation and risk management. Fixed-income securities may play a role in achieving these objectives, but investors should consider their investment horizon and liquidity needs." As investors navigate through dynamic market conditions, Foster West Securities remains committed to providing educational resources and personalised guidance to help clients make informed investment decisions. The firm emphasises the importance of understanding the potential risks and rewards associated with fixed-income investments and encourages investors to consult with financial professionals before making any investment decisions. About Foster West Securities: Foster West Securities PTY Ltd is a leading Australian-based wealth management company committed to delivering tailored financial solutions. With a focus on wealth preservation and growth, Foster West Securities assists clients in navigating the complexities of the financial landscape by providing comprehensive investment strategies and a range of financial services. For more information on Foster West Securities, please contact info@fosterwest.com.au or visit https://www.fosterwest.com.au. Contact Details Foster West Securities Angela Cameron info@fosterwest.com.au Company Website https://www.fosterwest.com.au

March 19, 2024 04:44 PM Eastern Daylight Time

Image

CORRECT AND REPLACE: Beal University’s Health Information Management Program Receives Initial Accreditation for Seven Years

Beal University

Beal University is proud to announce that its Health Information Management (HIM) Baccalaureate Degree Program has been awarded Initial Accreditation for Seven Years by the Commission on Accreditation for Health Informatics and Information Management Education (CAHIIM). The accreditation was granted following a comprehensive program review conducted by the Health Information Management Accreditation Council and the CAHIIM Board of Directors. The vote to award initial accreditation to Beal University’s HIM program took place on February 16, 2024. This accreditation underscores the program’s substantial compliance with the nationally established CAHIIM 2018 Health Information Management Accreditation Standards. Beal University’s HIM program has demonstrated a commitment to continuous quality improvement in higher education, as recognized by CAHIIM. “We are thrilled to receive initial accreditation for our Health Information Management Baccalaureate Degree Program,” said Sheryl DeWalt, MBA, CPA, President of Beal University. “This accreditation is a testament to the dedication and hard work of our faculty, staff, and students in upholding the highest standards of education in health informatics and information management.” The HIM program at Beal University equips students with the knowledge and skills necessary to succeed in the rapidly evolving field of health information management. Through a comprehensive curriculum and hands-on learning experiences, students gain expertise in managing health information systems, ensuring data accuracy and security, and utilizing technology to improve healthcare delivery. The CAHIIM accreditation serves as a mark of quality and excellence in health informatics and information management education. It signifies that Beal University’s HIM program meets or exceeds the rigorous standards set forth by CAHIIM, ensuring that graduates are well-prepared to excel in their careers as health information management professionals. Beal University is committed to delivering a high-quality education and real-world experiential opportunities that positions its graduates for success. Beal’s instructors have working experience in the health information industry and our curriculum aligns with the current environment. This accelerated but flexible online baccalaureate program can be completed in 38 months (about 3 years) for new students but is designed as a seamless stepladder approach that empowers our existing health information technology associate degree graduates to earn a bachelor’s degree with only 18 additional months. Beal University’s bachelor’s in HIM offers graduates a chance to improve advancement opportunities and earn one or more highly sought after credentials. The health information management Bachelor of Science program prepares students for various career pathways in health information and informatics, revenue cycle management, data quality and analytics, health information privacy, risk management, and health care compliance. With initial accreditation secured, Beal University’s HIM program will undergo a comprehensive program review for continuing accreditation in 2031-2032. The university looks forward to continuing its tradition of excellence in health informatics and information management education. For more information about Beal University’s Health Information Management Baccalaureate Degree Program, visit Beal University Health Information Management Program Contact Details Admission Department +1 207-307-3900 admissions@beal.edu

March 19, 2024 04:05 PM Eastern Daylight Time

IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1

IGC Pharma, Inc. (IGC)

By Faith Ashmore, Benzinga Alzheimer's disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact of Alzheimer’s disease makes it a major healthcare challenge. In 2023, Alzheimer’s and other types of dementia were projected to cost the U.S. $345 billion. By 2050, these costs could rise to nearly $1 trillion. While no cure currently exists for Alzheimer's, promising advancements in research and treatment are bringing hope to patients and their families. Hope On The Horizon? IGC Pharma (AMEX: IGC) is one of the companies hoping to provide solutions for millions of suffering Americans. It is a pharmaceutical company focused on developing innovative therapies for various medical conditions and fields, including Alzheimer's disease, chronic pain and women’s health. The company specializes in advanced formulas and the company’s lead drug candidate is IGC-AD1. IGC-AD1 is undergoing extensive clinical trials to evaluate its effectiveness and safety in treating Alzheimer's disease. The phase two clinical trial, initiated in 2023, encompasses 20 sites across the United States and Canada. With a target of 146 participants, this trial focuses on determining the efficacy of IGC-AD1 in alleviating agitation, a common symptom experienced by many Alzheimer's patients. IGC-AD1 has patent protection for its unique formulation, which involves a combination of two Active Pharmaceutical Ingredients (APIs). This combination is administered as an oral liquid solution, making it more accessible and convenient for patients. Pre-clinical studies of IGC-AD1 have demonstrated its potential in reducing the production of Aβ40 peptide and inhibiting the aggregation of Aβ42, both of which are associated with Alzheimer's. During phase one trials, patients with mild to severe Alzheimer's disease participated in a double-blind trial, where IGC-AD1 was administered at three different doses over a period of 14 days. The results were encouraging, as IGC-AD1 proved to be safe and well-tolerated by the participants, with no significant adverse effects reported. The study also demonstrated improvements in Neuropsychiatric Symptoms (NPS), specifically in the domains of agitation, anxiety and depression. These positive changes also led to a reduction in caregiver distress. With the success of phase one trials, the company expects the phase two clinical trial to provide further insights into the efficacy and safety of IGC-AD1. As researchers and healthcare professionals continue to investigate this potential treatment, IGC-AD1 could bring hope to the millions of individuals living with Alzheimer's disease and their loved ones. IGC Pharma also has four other drugs in the pipeline that are at the pre-clinal stage. TGR-63 targets early-moderate-stage Alzheimers and so far, has been shown to improve memory and learning in mice models at the pre-clinical stage. The other drugs in the company’s pipeline are 1C, M3, and LMP, and it also has a variety of patents that focus on a wide range of targets, from eating disorders to epilepsy and more. Featured photo by bruce mars on Unsplash IGC Pharma Inc. (IGC) is at the forefront of the fight against Alzheimer's disease, developing innovative solutions to address this devastating illness. The company's mission is to transform the landscape of Alzheimer's treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer's disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a Phase 2b clinical trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, CT05543681). TGR-63 disrupts the progression of Alzheimer's by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer's. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer's therapy. In addition to its drug development pipeline, IGC Pharma is actively leveraging Artificial Intelligence (AI) for Alzheimer's research. Their AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer's. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission ("SEC") filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, and Quarterly Report on Form 10-Q filed with the SEC on February 14, 2024, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Rosalyn Christian rchristian@imsinvestorrelations.com Company Website https://igcpharma.com/

March 19, 2024 04:00 PM Eastern Daylight Time

Image

CWG Markets' Triumph: Best Online Trading Service Award at Dubai's 2024 Trading Influence Awards

Rev Up Marketers

Dubai's 2024 Trading Influence Awards recently became the epicenter of celebration for the global trading community, with CWG Markets clinching the prestigious award for the "Best Online Trading Service." This triumph not only underscores CWG Markets' exceptional contribution to the online trading sector but also reflects the company's unwavering commitment to excellence and innovation. The Grand Night in Dubai: 2024 Trading Influence Awards Unveiled Set against the dazzling backdrop of Dubai, the 2024 Trading Influence Awards emerged as a beacon for the financial industry, bringing together industry leaders, innovators, and professionals from across the globe. It was more than an awards ceremony; it was a dynamic showcase of groundbreaking ideas, cutting-edge technologies, and the collaborative spirit that defines the essence of the trading industry. CWG Markets shone amidst this distinguished gathering, earning recognition for its outstanding online trading services. This accomplishment not only solidifies its position as a leader in the field but also sets the stage for a new era of excellence in the competitive world of online trading. The Pinnacle Achievement: "Best Online Trading Service Award" The pinnacle of CWG Markets' success at the 2024 Trading Influence Awards was undoubtedly the receipt of the "Best Online Trading Service Award." This accolade stands as a tribute to the company's unwavering dedication to providing a superior trading experience for its clients. Known for its robust and user-friendly platform, CWG Markets goes beyond the conventional to offer traders a comprehensive suite of tools and resources. The platform boasts advanced technology that ensures seamless trading, real-time market insights for informed decision-making, and a customer service team that is not only supportive but instrumental in helping traders navigate the markets confidently and efficiently. A Platform Redefining Standards CWG Markets has carved a niche for itself with its commitment to excellence in the online trading sector. The platform's user-friendly interface is designed to cater to both novice and experienced traders, providing a seamless and intuitive experience. The advanced technology integrated into the platform ensures that traders have access to cutting-edge tools, contributing to an environment conducive to success in the ever-evolving financial markets. Real-time market insights are a hallmark of CWG Markets, offering traders the information they need to make informed decisions. This commitment to empowering traders with knowledge is a key factor that sets CWG Markets apart in the competitive landscape. Additionally, the customer service team at CWG Markets plays a pivotal role in ensuring the satisfaction and success of traders. With a supportive and responsive approach, the team stands ready to assist clients, providing a level of service that goes beyond expectations. Gratitude and Aspirations: CWG Markets Responds to the Award Upon receiving the "Best Online Trading Service Award," a spokesperson for CWG Markets expressed heartfelt gratitude. "They are honored to receive this award, which stands as a testament to our team's hard work and dedication to excellence. At CWG Markets, they are committed to empowering their clients with innovative tools and exceptional service to help them succeed in the competitive world of online trading." The recognition at the 2024 Trading Influence Awards serves as a motivating factor for CWG Markets to continue enhancing its services and setting new standards in the industry. This acknowledgment not only celebrates past successes but also fuels the company's aspirations for the future. Enduring Commitment: Quality, Innovation, and Customer Satisfaction CWG Markets' triumph at the 2024 Trading Influence Awards is not merely a momentary acknowledgment but a reflection of its enduring commitment to quality, innovation, and customer satisfaction. The "Best Online Trading Service Award" is a symbol of the company's dedication to excellence, and it positions CWG Markets as a trailblazer in leading the online trading industry toward new horizons. As the financial landscape continues to evolve, CWG Markets remains poised to adapt and innovate. This award serves as a testament to the company's ability to navigate challenges and consistently deliver exceptional services to its clients. Leading the Way into the Future of Online Trading CWG Markets ' triumph at Dubai's 2024 Trading Influence Awards signifies not only a recognition of past achievements but also a commitment to shaping the future of online trading. The company's dedication to providing a superior trading experience, coupled with its innovative approach and unwavering commitment to customer satisfaction, sets a benchmark for the industry. As CWG Markets looks ahead, the "Best Online Trading Service Award" serves as a reminder of the responsibility to continue leading the way, setting new standards, and empowering traders to navigate the complexities of the financial markets with confidence. The triumph in Dubai is not just an accolade; it's a proclamation that CWG Markets is at the forefront of the online trading industry, ready to embrace the challenges and opportunities that lie ahead. Contact Details CWG Markets Will +60 1-800-81-9380 complaint@cwgmarkets.com Company Website https://cwgmarkets.com/

March 19, 2024 03:09 PM Eastern Daylight Time

Image

Avenix Fzco Unveils Groundbreaking Trading Software for Enhanced Market Strategy

Rev Up Marketers

Avenix Fzco, a pioneering financial technology company, has announced the launch of its innovative trading software, specifically designed for traders focusing on the XAUUSD pair and the H1 timeframe. This groundbreaking tool is set to revolutionize the trading experience by integrating precision strategy, optimized risk management, and intelligent auto-lot functionality. The software, developed by a team of expert traders and technologists, addresses key challenges faced by modern traders. With its precision strategy feature, traders can navigate the complexities of the gold market with greater accuracy and confidence. The optimized risk management system ensures that traders can minimize potential losses while maximizing gains. Additionally, the intelligent auto-lot functionality adapts to market conditions and the trader’s risk profile, making trading more efficient and effective. Botogon is a forex robot that stands out for its user-friendly interface and robust analytical tools. It is designed to cater to both novice and experienced traders, offering a seamless and intuitive trading experience. The software’s advanced algorithms and real-time market analysis provide traders with an edge in a fast-paced trading environment. Apart from the software, Avenix Fzco is committed to building a supportive trading community. This community provides an interactive platform where traders can share insights, learn from each other, and grow together. The community aspect emphasizes the company's dedication to not only offering top-notch tools but also nurturing a learning and collaborative environment. As Avenix Fzco continues to innovate in the fintech space, the company remains focused on its mission to empower traders with state-of-the-art tools and a supportive community. About Avenix Fzco: Avenix Fzcois a financial technology company based in Dubai, UAE. The company specializes in developing advanced trading software with a focus on precision, risk management, and intelligent functionality. Avenix Fzco commitment to innovation and community support makes it a leader in the fintech industry. For more information, visit: botogon.com Contact Details Avenix Fzco Media Relation Team support@botogon.com Company Website https://botogon.com

March 19, 2024 03:00 PM Eastern Daylight Time

Image

Beal University’s Health Information Management Program Receives Initial Accreditation for Seven Years

Beal University

Beal University is proud to announce that its Health Information Management (HIM) Baccalaureate Degree Program has been awarded Initial Accreditation for Seven Years by the Commission on Accreditation for Health Informatics and Information Management Education (CAHIIM). The accreditation was granted following a comprehensive program review conducted by the Health Information Management Accreditation Council and the CAHIIM Board of Directors. The vote to award initial accreditation to Beal University’s HIM program took place on February 16, 2024. This accreditation underscores the program’s substantial compliance with the nationally established CAHIIM 2018 Health Information Management Accreditation Standards. Beal University’s HIM program has demonstrated a commitment to continuous quality improvement in higher education, as recognized by CAHIIM. “We are thrilled to receive initial accreditation for our Health Information Management Baccalaureate Degree Program,” said Sheryl DeWalt, MBA, CPA, President of Beal University. “This accreditation is a testament to the dedication and hard work of our faculty, staff, and students in upholding the highest standards of education in health informatics and information management.” The HIM program at Beal University equips students with the knowledge and skills necessary to succeed in the rapidly evolving field of health information management. Through a comprehensive curriculum and hands-on learning experiences, students gain expertise in managing health information systems, ensuring data accuracy and security, and utilizing technology to improve healthcare delivery. The CAHIIM accreditation serves as a mark of quality and excellence in health informatics and information management education. It signifies that Beal University’s HIM program meets or exceeds the rigorous standards set forth by CAHIIM, ensuring that graduates are well-prepared to excel in their careers as health information management professionals. Beal University is committed to delivering a high-quality education and real-world experiential opportunities that positions its graduates for success. Beal’s instructors have working experience in the health information industry and our curriculum aligns with the current environment. This accelerated but flexible online baccalaureate program can be completed in 38 months (about 3 years) for new students but is designed as a seamless stepladder approach that empowers our existing health information technology associate degree graduates to earn a bachelor’s degree with only 18 additional months. Beal University’s bachelor’s in HIM offers graduates a chance to improve advancement opportunities and earn one or more highly sought after credentials. The health information management Bachelor of Science program prepares students for various career pathways in health information and informatics, revenue cycle management, data quality and analytics, health information privacy, risk management, and health care compliance. With initial accreditation secured, Beal University’s HIM program will undergo a comprehensive program review for continuing accreditation in 2031-2032. The university looks forward to continuing its tradition of excellence in health informatics and information management education. For more information about Beal University’s Health Information Management Baccalaureate Degree Program, visit Beal University Health Information Management Program Contact Details Beal University Beal University Admissions +1 800-660-7351 admissions@bealuniversity.ca

March 19, 2024 02:48 PM Eastern Daylight Time

Shaping the Future of Healthcare: Benzinga Virtual Healthcare Summit 2024

Benzinga

Benzinga is thrilled to present the 2024 Virtual Healthcare Summit, a groundbreaking virtual event poised to revolutionize the landscape of healthcare. This summit is a beacon of innovation, bringing together leading companies, healthcare visionaries, analysts, asset managers, and thought leaders to shape the future of health. Scheduled for Wednesday, March 20, starting at 10:25 AM EST, this summit is set to attract tens of thousands of attendees eager to explore the latest advancements and insights driving the healthcare industry forward. Our esteemed sponsors for the event include: The Beachbody Company Cardio Diagnostics Holdings, Inc. Elicio Therapeutics Theriva Biologics, Inc. First Wave BioPharma Plus Therapeutics BioHarvest Sciences ZyVersa Therapeutics IN8Bio, Inc. IGC Pharma Atossa Therapeutics Autonomix Medical, Inc. AXIM Biotechnologies ImmunoPrecise Antibodies Ltd. The agenda for the summit features an impressive lineup of speakers, including: Don Duffy, President at ICR John Huemoeller, CEO at AXIM Biotechnologies Steve A. Shallcross, CEO at Theriva Biologics Manel Cascallo, General Director, EU Subsidiary at Theriva Biologics Laura Chico, PhD, Senior Vice President, Equity Research Freda Lewis-Hall; Michael O'Brian, Partner & Head of US Healthcare PR at ICR & Westwicke David Song, Investment Partner and Head of Life Sciences at TEMA ETFs Lori Bisson, CEO at Autonomix Medical Steven Qua, MD, PhD, President & CEO at Atossa Therapeutics Ilan Sobel, CEO at BioHarvest Sciences Ram Mukunda, CEO at IGC Pharmaceuticals Claudia Grimaldi, VP, CCO, PFO, & Director at IGC Pharmaceuticals Mark Klausner, Managing Director, Head of U.S. Healthcare Investor Relations at ICR Westwicke Adam Mendelsohn, PH.D., Co-Founder & CEO at Vivani Medical Meesha Dogan, CEO, Co-founder & Director at Cardio Diagnostics Steve Glover, Co-founder, Chairman, CEO, & President at ZyVersa Therapeutics Robert Jacks, President & CEO at Sparrow Pharmaceuticals Marc Hedrick, President & CEO at Plus Therapeutics William Ho, CEO at IN8Bio, Inc Mark Goldston, Executive Chairman at The Beachbody Company Dr. Jennifer Bath, CEO at Immunoprecise Antibodies Ltd. Robert Connelly, CEO at Elicio Therapeutics Sameer Khambadkone, Managing Director at ICR/Westwicke Each speaker brings invaluable expertise and perspectives, promising enriching discussions that will shape the future of healthcare. Join us as we embark on this transformative journey in healthcare. Registration is now open, and participation is free. Don't miss the opportunity to be part of this historic event and contribute to shaping the future of health. For more information and to register, visit the event registration page. Drew Pilat Benzinga 1 Campus Martius, Detroit, MI 48226 drew@benzinga.com benzinga.com/events Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. Contact Details Benzinga +1 877-440-9464 drew@benzinga.com Company Website http://www.benzinga.com

March 19, 2024 02:00 PM Eastern Daylight Time

1 ... 330 331 332 333 334 ... 3755